Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Dermatology by Phase

  • There are currently 1379 ongoing clinical trials involving Dermatology

  • Of the 1379 trials,559 trials are in Phase II

  • Furthermore, 432 trials are in Phase III

Number of ongoing Clinical Trials (for drugs) involving Dermatology by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Dermatology therapy area. The largest number of ongoing clinical trials for Dermatology therapy area is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions involved in Dermatology-related drug trials.

Novartis AG: The leading ongoing Dermatology related clinicaltrialsponsor

Novartis AG, the Switzerland based pharmaceutical company, is the top sponsor for Dermatology-related ongoing clinical trials.

Galderma SA, Eli Lilly and Co, Isfahan University of Medical Sciences, and Pfizer Inc are a few other notable clinicaltrial sponsors involving Dermatology. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Dermatology

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis), Upadacitinib (Rinvoq, Rim-Voq), and Onabotulinumtoxin A (Botox) are among the key marketed drugs involving Dermatology.

Dupilumab (REGN-668, SAR231893, Dupixent, Dubrantis) is a monoclonal antibody developed based on VelocImmune technology. It functions via Interleukin 4 Receptor Subunit Alpha (CD124 or IL4R) Antagonist mechanism of action.It is formulated as an injectable solution and injectable powder for solution for subcutaneous route of administration. Dupilumabwas first approved in 2017 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by several prominent pharma giants including Sanofi-Aventis US LLC.

Upadacitinib (Rinvoq, Rim-Voq) is an antineoplastic drug, acts as immunosuppressive agent. It functions via Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Inhibitormechanism of action.  It is formulated as extended release tablets, extended release coated tablets and extended release film coated tablets for oral route of administration.Upadacitinib was first approved in 2019 and is marketed globally including the US, the UK, France, Germany, and Japan by AbbVie Inc.



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward